Looking to fight Leukemia: Syros Pharmaceuticals files for a $69 million IPO

Looking to fight Leukemia: Syros Pharmaceuticals files

Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, filed on Friday with the SEC to raise up to $69 million in an initial public offering.

The Cambridge, MA-based company was founded in 2011. It plans to list on the Nasdaq under the symbol SYRS. Cowen & Company and Piper Jaffray are the joint book runners on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.